Helsinn closes financing agreement with BancaStato to support business objectives and growth
10. Oktober 2023 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
21. September 2022 08:34 ET
|
Helsinn Healthcare S.A.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and real-world settings will be presentedHelsinn...
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
08. August 2022 04:07 ET
|
Helsinn Healthcare S.A.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
03. März 2022 07:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
20. Dezember 2021 08:03 ET
|
Helsinn Healthcare S.A.
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)
23. September 2020 04:43 ET
|
Helsinn Healthcare S.A.
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) Lugano, Switzerland,...
Helsinn to co-host MF-CTCL satellite symposium alongside Recordati Rare Diseases at the EADV 2019 Congress GNW: European only
09. Oktober 2019 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland,...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
19. September 2019 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
19. März 2019 18:00 ET
|
Helsinn Healthcare S.A.
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn...
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
14. Februar 2019 15:22 ET
|
Helsinn Healthcare S.A.
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood...